Vertex wins once-rejected Kalydeco label expansion, bumping guidance by $30M-plus

19th May 2017 Uncategorised 0

Last February, the FDA nixed Vertex’s bid to expand cystic fibrosis med Kalydeco to patients with specific mutations in the CFTR gene. Wednesday, though, the Cambridge drugmaker finally got what it wanted.

More: Vertex wins once-rejected Kalydeco label expansion, bumping guidance by M-plus
Source: fierce